Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
The American Journal of Pathology|January 13, 2011
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinomaFrancesca Zammarchi, Mariangela Morelli, Michele Menicagli, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Neuro-Oncology|January 18, 2025
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targetsNathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, et al.
Theranostics|March 21, 2020
Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virusKate M Moore, Ami Desai, Bea de Luxán Delgado, et al.
Blood|January 5, 2018
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignanciesFrancesca Zammarchi, Simon Corbett, Lauren Adams, et al.
Molecular Cancer Therapeutics|February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic MalignanciesFrancesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 29, 2024
Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplantJenny Yeung, Aiyin Liao, Matthew Shaw, et al.
Scientific Reports|July 12, 2018
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirineJohn A Hartley, Michael J Flynn, John P Bingham, et al.
Haematologica|May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapyChiara Tarantelli, David Wald, Nicolas Munz, et al.
Pageof 3